We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Mazdutideis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Mazdutide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2021–2026 with a typical study size of 250 participants.
Based on 13 studies · 2 meta-analyses · 10 RCTs · 3,482 total participants
Confidence
HighBy outcome
Mazdutide has an evidence score of 5/10 — moderate evidence based on 13 indexed studies, including 2 meta-analyses. An investigational once-weekly injectable GLP-1 and glucagon receptor dual agonist (an oxyntomodulin analogue, IBI362/LY3305677) developed mainly in China by Innovent and Eli Lilly for obesity and type 2 diabetes. Honest appraisal: real phase-2 and phase-3 randomized trials show clinically meaningful weight loss (~12-17% at higher doses) and HbA1c reduction, but the evidence is almost entirely single-region (Chinese) and recent. It was approved in China in 2025 — it is NOT FDA-approved and is not available or approved in the West. It is a prescription drug, not a dietary supplement. Representative study: PMID 41804840.
The commonly studied dose of Mazdutide is Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Semaglutide
Mostly mechanism / observationalAn FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is included here for reference only, not as a supplement and not auto-recommended.
Last reviewed June 2026 · evidence from 13 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Mazdutide (GLP-1 / glucagon receptor dual agonist)
An investigational once-weekly injectable GLP-1 and glucagon receptor dual agonist (an oxyntomodulin analogue, IBI362/LY3305677) developed mainly in China by Innovent and Eli Lilly for obesity and type 2 diabetes. Honest appraisal: real phase-2 and phase-3 randomized trials show clinically meaningful weight loss (~12-17% at higher doses) and HbA1c reduction, but the evidence is almost entirely single-region (Chinese) and recent. It was approved in China in 2025 — it is NOT FDA-approved and is not available or approved in the West. It is a prescription drug, not a dietary supplement.
Moderate score reflects methodologically sound phase-2/3 RCTs and meta-analyses showing large weight loss and HbA1c reductions, tempered by recent, almost entirely single-region (Chinese) data, no FDA approval, and no long-term outcomes.
Mazdutide (development codes IBI362 / LY3305677; Chinese brand Xinermei) is a once-weekly subcutaneous peptide that activates two receptors at once: the glucagon-like peptide-1 (GLP-1) receptor and the glucagon (GCGR) receptor. It is an analogue of oxyntomodulin, a gut hormone that naturally engages both receptors.
GLP-1 agonism suppresses appetite and slows gastric emptying; adding glucagon agonism is intended to raise energy expenditure and reduce hepatic fat, on top of the GLP-1 weight-loss effect. It is co-developed by Innovent Biologics and Eli Lilly.
In June 2025 it received its first approval — in China — for long-term weight management in adults (BMI >=28, or >=24 with a weight-related comorbidity), and in September 2025 a second China approval for glycemic control in type 2 diabetes.
It is NOT approved by the FDA, EMA, or other Western regulators, and is investigational outside China.
The clinical evidence is genuine but geographically narrow: phase-1b multiple-ascending-dose trials (2021-2022) established tolerability and dose-dependent weight loss; phase-2 trials in Chinese adults with overweight/obesity showed ~6.7-11.3% weight loss at 24 weeks (3-6 mg) and ~12.8% at 9 mg, and a phase-2 T2D trial showed HbA1c reductions of ~1.4-1.7% with weight loss, superior to dulaglutide.
The pivotal phase-3 program (GLORY) reported ~11-14% weight loss at 48 weeks (4/6 mg, GLORY-1) and ~16.7% at 60 weeks (9 mg, GLORY-2) versus placebo, plus phase-3 T2D trials showing HbA1c reductions up to ~2.2% (monotherapy vs placebo) and superiority to dulaglutide.
Beneficial effects on blood pressure and lipids were consistently seen. The most frequent adverse effects are gastrointestinal (nausea, vomiting, diarrhea) — notably common at the 9 mg dose (vomiting ~53%, nausea ~47% in GLORY-2) — mostly mild-to-moderate and concentrated during dose escalation.
Because it also agonizes the glucagon receptor, class-level questions about heart rate and hepatic effects warrant monitoring, and long-term outcome data are not yet available.
This is a prescription drug under investigation in the West, not a supplement; anything sold as 'mazdutide' outside a legitimate Chinese prescription is grey-market material of unverified identity, purity, and dose.
Mazdutide is a single oxyntomodulin-analogue peptide that activates both the GLP-1 receptor and the glucagon (GCGR) receptor — the basis for its 'dual agonist' classification, combining GLP-1-driven appetite suppression with glucagon-driven energy expenditure and hepatic effects.
Through GLP-1 agonism it suppresses appetite and slows gastric emptying, reducing food intake — the main driver of the weight loss seen across the GLORY phase-3 program.
Glucagon-receptor agonism is intended to increase energy expenditure and reduce liver fat, an effect proposed to add to GLP-1-driven weight loss — though the glucagon arm also raises class-level monitoring questions (heart rate, hepatic, glucose).
How Mazdutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Investigational / China-only dosing: once-weekly subcutaneous injection, dose-escalated over several weeks. Trial maintenance doses studied were 4 mg, 6 mg, and 9 mg once weekly (lower doses used during titration to limit GI effects). There is no FDA-approved regimen.
Can be taken without food
| Form | Type |
|---|---|
| 💊Once-weekly subcutaneous injection (investigational; China-approved as Xinermei) | Recommended |
| 💊Tirzepatide (FDA-approved GIP/GLP-1 dual agonist) | Alternative |
| 💊Semaglutide (FDA-approved selective GLP-1 agonist) | Alternative |
Unlike tirzepatide and semaglutide, mazdutide is not FDA-approved and is investigational in the West. Only a legitimate Chinese prescription product has verified identity, purity, and dose.
Compare Mazdutide vs Tirzepatide →Minimum: 24 weeks
Optimal: 60 weeks
Cycling: Not required
Note: Once weekly, same day each week, with or without food. The dose is escalated slowly to limit GI side effects, which are pronounced at the 9 mg dose.
Dose-response data unavailable. The current published research for Mazdutide does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Phase-3 trials showed ~11-14% weight loss at 48 weeks (4/6 mg, GLORY-1) and ~16.7% at 60 weeks (9 mg, GLORY-2) versus placebo in Chinese adults — robust, but in a single-region population.
Lowered HbA1c by up to ~2.2% vs placebo (phase-3 monotherapy) and was superior to dulaglutide head-to-head, with concurrent weight loss.
Meta-analyses report reductions in systolic blood pressure (~-7.7 mmHg), total cholesterol, and LDL — consistent secondary cardiometabolic benefits.
Nausea, vomiting, and diarrhea are common and rise sharply at higher doses — in GLORY-2 (9 mg) vomiting affected ~53% and nausea ~47%, mostly mild-to-moderate and worst during escalation.
Approved in China (2025) but not by the FDA or EMA. Outside a Chinese prescription, any 'mazdutide' is unverified grey-market material — a major real-world risk.
Investigational and not approved — there is no legitimate, quality-assured supply outside a Chinese prescription. Do not use grey-market material.
Use with caution or avoid; monitor for pancreatitis symptoms.
Hypoglycemia risk — concomitant doses may need reduction under medical supervision.
Contraindicated — not studied in pregnancy and weight loss is not recommended during pregnancy.
Additive glucose-lowering raises hypoglycemia risk; concomitant doses may need reduction under medical supervision.
Delayed gastric emptying can alter the absorption of co-administered oral drugs; most relevant for narrow-therapeutic-index agents and oral contraceptives.
Tip: Slow dose escalation; smaller meals; usually eases after titration
Tip: Slower escalation; especially frequent at the 9 mg dose
Tip: Hydration; slower escalation
Tip: Expected effect; ensure adequate protein intake
Tip: Monitor; the glucagon arm warrants attention to heart rate — report palpitations
Timing is flexible for Mazdutide — consistent daily use matters more than the time of day. Administered once weekly on the same day, with or without food.
Mazdutide should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are nausea, vomiting, diarrhea. Use caution if any of these apply to you: Pregnancy and breastfeeding; Personal or family history of medullary thyroid carcinoma or MEN2 (class-level precaution for GLP-1-based agents); History of pancreatitis (use with caution / avoid).
Tirzepatide
Mostly mechanism / observationalAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Overall the evidence is moderate: methodologically sound phase-2/3 RCTs, but recent, mostly single-region, and not yet FDA-approved.
Enhances glucose-dependent insulin secretion via GLP-1 agonism, lowering HbA1c and fasting glucose in type 2 diabetes trials, with weight loss as a co-benefit.
Tip: Stop and seek care for severe persistent abdominal pain; avoid with a pancreatitis history